Fredun Pharmaceuticals Ltd — Important, 25-05-2026: Company Update

Fredun Pharmaceuticals announced a 2:1 bonus issue of equity shares, meaning shareholders will receive two new shares for every one held. The Board, after approving Q4 and FY26 audited financial results, approved the proposal for this bonus, signaling strong confidence in future growth and business scalability. The company achieved FY26 revenues of ₹639.12 Cr, EBITDA of ₹94.79 Cr, and PAT of ₹33.21 Cr. With new facilities and diversified product lines, Fredun is positioned for sustained growth and long-term shareholder value creation.